-
2
-
-
31144460322
-
Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: Unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis
-
Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006;65:149-56.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 149-156
-
-
Walker, J.G.1
Ahern, M.J.2
Coleman, M.3
-
3
-
-
0028206119
-
JAK3: A novel JAK kinase associated with terminal differentiation of hematopoietic cells
-
Rane SG, Reddy EP. JAK3: A novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994;9:2415-23.
-
(1994)
Oncogene
, vol.9
, pp. 2415-2423
-
-
Rane, S.G.1
Reddy, E.P.2
-
4
-
-
0031919849
-
Jaks and STATs: Biological implications
-
Leonard WJ, OShea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322.
-
(1998)
Annu Rev Immunol
, vol.16
, pp. 293-322
-
-
Leonard, W.J.1
Oshea, J.J.2
-
5
-
-
84881119287
-
Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: Secondary analysis from a large clinical trial
-
Baker JF, Ostergaard M, Emery P, et al. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial. Ann Rheum Dis 2014;73:1968-74.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 1968-1974
-
-
Baker, J.F.1
Ostergaard, M.2
Emery, P.3
-
6
-
-
45349090842
-
Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: Bone marrow oedema predicts erosive progression
-
Haavardsholm EA, Bøyesen P, Østergaard M, et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008;67:794-800.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 794-800
-
-
Haavardsholm, E.A.1
Bøyesen, P.2
Østergaard, M.3
-
7
-
-
61549139043
-
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis Results from a 2-year randomised controlled trial (CIMESTRA)
-
Hetland ML, Ejbjerg B, Hørslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 384-390
-
-
Hetland, M.L.1
Ejbjerg, B.2
Hørslev-Petersen, K.3
-
8
-
-
84893583879
-
The OMERACT-RAMRIS rheumatoid arthritis magnetic resonance imaging joint space narrowing score: Intrareader and interreader reliability and agreement with computed tomography and conventional radiography
-
Døhn UM, Conaghan PG, Eshed I, et al. The OMERACT-RAMRIS rheumatoid arthritis magnetic resonance imaging joint space narrowing score: intrareader and interreader reliability and agreement with computed tomography and conventional radiography. J Rheumatol 2014;41:392-7.
-
(2014)
J Rheumatol
, vol.41
, pp. 392-397
-
-
Døhn, U.M.1
Conaghan, P.G.2
Eshed, I.3
-
9
-
-
84971329257
-
Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis
-
Baker JF, Conaghan PG, Emery P, et al. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. Ann Rheum Dis 2016;75:1114-9.
-
Ann Rheum Dis
, vol.2016
, Issue.75
, pp. 1114-1119
-
-
Baker, J.F.1
Conaghan, P.G.2
Emery, P.3
-
10
-
-
84922808076
-
A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis
-
Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 2015;67:334-43.
-
(2015)
Arthritis Rheumatol
, vol.67
, pp. 334-343
-
-
Fleischmann, R.M.1
Damjanov, N.S.2
Kivitz, A.J.3
-
11
-
-
84952050201
-
VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis
-
Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 2016;68:46-55.
-
Arthritis Rheumatol
, vol.2016
, Issue.68
, pp. 46-55
-
-
Genovese, M.C.1
Van Vollenhoven, R.F.2
Pacheco-Tena, C.3
-
12
-
-
19944430372
-
An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image Atlas
-
Østergaard M, Edmonds J, McQueen F, et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image Atlas. Ann Rheum Dis 2005;64(Suppl 1):i3-7.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. i3-7
-
-
Østergaard, M.1
Edmonds, J.2
McQueen, F.3
-
13
-
-
84880206715
-
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: The ASSET randomised controlled trial
-
Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: The ASSET randomised controlled trial. Ann Rheum Dis 2013;72:1287-94.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 1287-1294
-
-
Conaghan, P.G.1
Durez, P.2
Alten, R.E.3
-
14
-
-
80053563603
-
Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: Results of the GO-FORWARD trial
-
Conaghan PG, Emery P, Østergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1968-1974
-
-
Conaghan, P.G.1
Emery, P.2
Østergaard, M.3
-
15
-
-
84897983379
-
The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: Results from the ACT-RAY MRI substudy
-
Conaghan PG, Peterfy C, Olech E, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis 2014;73:810-16.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 810-816
-
-
Conaghan, P.G.1
Peterfy, C.2
Olech, E.3
-
16
-
-
84933074076
-
MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: A randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0 1, 2, 4, 8 and 16
-
Østergaard M, Jacobsson LT, Schaufelberger C, et al. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: A randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Ann Rheum Dis 2015;74:1156-63.
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 1156-1163
-
-
Østergaard, M.1
Jacobsson, L.T.2
Schaufelberger, C.3
-
17
-
-
84954208482
-
MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: Results from the randomised, placebo-controlled, double-blind RA-SCORE study
-
Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis 2016;75:170-7.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 170-177
-
-
Peterfy, C.1
Emery, P.2
Tak, P.P.3
|